Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET.
Sinan WangJun LiJun HuaYang SuDenis R Beckford-VeraWalter ZhaoMayuri JayaramanTony L HuynhNing ZhaoYangjie HuangFujun QinSui ShenDaniel GioeliRobert DreicerRenuka SriramEmily A EgusaJonathan ChouFelix Y FengRahul AggarwalKenneth W BaylesYoungho SeoBin LiuRobert R FlavellJiang HePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
[89Zr]DFO-YS5 is an excellent PET imaging agent across a panel of prostate cancer models, including in both adenocarcinoma and neuroendocrine prostate cancer, both cell line- and patient-derived xenografts, and both PSMA-positive and -negative tumors. It demonstrates potential for clinical translation as an imaging agent, theranostic platform, and companion biomarker in prostate cancer.